Immune Checkpoint Inhibition in Locally Advanced Periocular Squamous Cell Carcinoma (POLA-SCC).
Yuval Tal, Daphna Landau-Prat, Or Gil et al.
✦ AI-curated · Sources linked
Case in brief
A 75-year-old man presented with recurrent upper eyelid squamous cell carcinoma (SCC) that persisted despite multiple surgical excisions and reconstructive efforts, leading to significant eyelid dysfunction and visual decline. Treatment with the PD-1 inhibitor cemiplimab resulted in meaningful tumor control and stabilization of the disease, highlighting the potential of immunotherapy in managing advanced periocular SCC.
Diagnostic / clinical pearl
Clinicians should consider PD-1 inhibitors as a viable treatment option for locally advanced periocular squamous cell carcinoma, especially in cases with recurrent disease where surgical options are limited.
Why it matters
This case underscores the role of immune checkpoint inhibitors in reducing the need for extensive surgical interventions, thereby preserving ocular function and improving patient quality of life.